Peter D Reaven

Phoenix VA Health Care System, Phoenix, Arizona, United States

Are you Peter D Reaven?

Claim your profile

Publications (110)723.54 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: The Veterans Affairs Diabetes Trial previously showed that intensive glucose lowering, as compared with standard therapy, did not significantly reduce the rate of major cardiovascular events among 1791 military veterans (median follow-up, 5.6 years). We report the extended follow-up of the study participants. After the conclusion of the clinical trial, we followed participants, using central databases to identify procedures, hospitalizations, and deaths (complete cohort, with follow-up data for 92.4% of participants). Most participants agreed to additional data collection by means of annual surveys and periodic chart reviews (survey cohort, with 77.7% follow-up). The primary outcome was the time to the first major cardiovascular event (heart attack, stroke, new or worsening congestive heart failure, amputation for ischemic gangrene, or cardiovascular-related death). Secondary outcomes were cardiovascular mortality and all-cause mortality. The difference in glycated hemoglobin levels between the intensive-therapy group and the standard-therapy group averaged 1.5 percentage points during the trial (median level, 6.9% vs. 8.4%) and declined to 0.2 to 0.3 percentage points by 3 years after the trial ended. Over a median follow-up of 9.8 years, the intensive-therapy group had a significantly lower risk of the primary outcome than did the standard-therapy group (hazard ratio, 0.83; 95% confidence interval [CI], 0.70 to 0.99; P=0.04), with an absolute reduction in risk of 8.6 major cardiovascular events per 1000 person-years, but did not have reduced cardiovascular mortality (hazard ratio, 0.88; 95% CI, 0.64 to 1.20; P=0.42). No reduction in total mortality was evident (hazard ratio in the intensive-therapy group, 1.05; 95% CI, 0.89 to 1.25; P=0.54; median follow-up, 11.8 years). After nearly 10 years of follow-up, patients with type 2 diabetes who had been randomly assigned to intensive glucose control for 5.6 years had 8.6 fewer major cardiovascular events per 1000 person-years than those assigned to standard therapy, but no improvement was seen in the rate of overall survival. (Funded by the VA Cooperative Studies Program and others; VADT ClinicalTrials.gov number, NCT00032487.).
    New England Journal of Medicine 06/2015; 372(23):2197-206. DOI:10.1056/NEJMoa1414266 · 54.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rosiglitazone may be associated with increased risk of cardiovascular (CV) disease in patients with type 2 diabetes (T2D). We evaluated the relationship between patterns of rosiglitazone use and CV outcomes in the Veterans Affairs Diabetes Trial (VADT). Time-dependent survival analyses, case-control and 1:1 propensity matching approaches were used to examine this relationship in the VADT, a randomized controlled study that assessed the effect of intensive glycemic control on CV outcomes in 1791 T2D patients (mean age of 60.4 ± 9 years). Participants were recruited from December 1, 2000, through May 31, 2003, and were followed for 5 to 7.5 years (median 5.6) with the final visit by May 31, 2008. Rosiglitazone (4 mg and 8 mg daily) was initiated per protocol in both intensive-therapy and standard-therapy groups. Main outcomes include a composite CV outcome, CV death, and myocardial infarction (MI). Both daily doses of rosiglitazone were associated with lower risk for the primary composite CV outcome (HR 0.63; 95% CI 0.49-0.81 and HR 0.60; 95% CI 0.49-0.75, respectively) after adjusting for demographic and clinical covariates. A reduction of CV death was also observed (HR 0.25, p < 0.001, for both 4 and 8 mg/day rosiglitazone), however the effect on MI was less evident for 8 mg/day and not significant for 4 mg/day. In older patients with T2D the use of rosiglitazone was associated with decreased risk of the primary CV composite outcome and CV death. Rosiglitazone use did not lead to higher risk of MI. This article is protected by copyright. All rights reserved.
    Diabetes Obesity and Metabolism 05/2015; DOI:10.1111/dom.12487 · 5.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular (CV) disease is the leading cause of mortality and morbidity in patients with type 2 diabetes mellitus (T2DM). However, improving glycaemic control alone has not decreased CV events. Therapies that improve glycaemic control, CV disease risk factors and CV function are more likely to be successful. Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent breakdown of incretin hormones glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic peptide and improve glycaemic control in patients with T2DM. DPP-4 acts on other substrates, many associated with cardioprotection. Thus, inhibition of DPP-4 may lead to elevations in these potentially beneficial substrates. Data from animal studies and small observational studies in humans suggest that DPP-4 inhibitors may potentially reduce CV risk. However, recently completed CV outcome trials in patients with T2DM and CV disease or at high risk of adverse CV events have shown that the DPP-4 inhibitors saxagliptin and alogliptin neither increased nor decreased major adverse CV events. © The Author(s) 2015.
    Diabetes & Vascular Disease Research 05/2015; 12(3):154-163. DOI:10.1177/1479164114562411 · 3.04 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: GLP-1 receptor (GLP-1R) agonists may improve endothelial function (EF) via metabolic improvement and direct vascular action. The present study determined the effect of GLP-1R agonist exenatide on postprandial EF in type 2 diabetes and the mechanisms underlying GLP-1R agonists-mediated vasodilation.Two crossover studies were conducted: 36 participants with type 2 diabetes received subcutaneous exenatide or placebo for 11 days and EF, glucose and lipid responses to breakfast and lunch were determined; 32 participants with impaired glucose tolerance (IGT) or diet-controlled type 2 diabetes had EF measured before and after intravenous exenatide, with or without the GLP-1R antagonist exendin-9. Mechanisms of GLP-1R agonist action were studied ex vivo on human subcutaneous adipose tissue arterioles and endothelial cells.Subcutaneous exenatide increased postprandial EF independent of reductions in plasma glucose and triglycerides. Intravenous exenatide increased fasting EF and exendin-9 abolished this effect. Ex vivo, exenatide elicited a dose-dependent vasorelaxation and reduced high-glucose or lipid-induced endothelial dysfunction in arterioles, and eNOS activation and NO production in endothelial cells. These effects were reduced with AMP-kinase inhibition.Exenatide augmented postprandial EF in subjects with diabetes and prevented high-glucose and lipid-induced endothelial dysfunction in human arterioles. These effects were largely direct, via GLP-1R and AMP-kinase activation. © 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
    Diabetes 02/2015; DOI:10.2337/db14-0976 · 8.47 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Using mass spectrometric immunoassay, the abundance of SAA truncations relative to the native variants was examined in plasma of 91 participants with type 2 diabetes and chronic kidney disease and 69 participants without diabetes. The ratio of SAA 1.1 (missing N-terminal arginine) to native SAA 1.1 was lower in diabetics compared to non-diabetics (p = 0.004), and in males compared to females (p<0.001). This ratio was negatively correlated with glycated hemoglobin (r = -0.32, p<0.001) and triglyceride concentrations (r = -0.37, p<0.001), and positively correlated with HDL cholesterol concentrations (r = 0.32, p<0.001). The relative abundance of the N-terminal arginine truncation of SAA1.1 is significantly decreased in diabetes and negatively correlates with measures of glycemic and lipid control.
    PLoS ONE 01/2015; 10(1):e0115320. DOI:10.1371/journal.pone.0115320 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To test the clinical utility of Quantose M(Q) to monitor changes in insulin sensitivity following pioglitazone therapy in prediabetic subjects. M(Q) is derived from fasting measurements of insulin, α-hydroxybutyrate, linoleoyl-glycerophosphocholine, and oleate, three non-glucose metabolites shown to correlate with insulin-stimulated glucose disposal., Research design and methods: Participants were 428 of the total of 602 ACT NOW IGT subjects randomized to pioglitazone (45 mg/day) or placebo and followed for, 2.4 years. At baseline and study end fasting plasma metabolites required for determination of Quantose, HbA1c, and OGTT with frequent plasma insulin and glucose measurements to calculate, Matsuda Index of insulin sensitivity were obtained. Results: Pioglitazone treatment lowered IGT conversion to diabetes (HR=0.25, 95%CI = 0.13-0.50, p<0.0001). While HbA1c did not track with insulin sensitivity, M(Q) increased in pioglitazone-treated subjects (by 1.45[3.45] mg(.)min(-1.)kgwbm(-1) (median[interquartile range]), (p<0.001 vs placebo) as did, Matsuda Index (by 3.05[4.77] units, p<0.0001). M(Q) correlated with Matsuda Index at baseline and change in Matsuda Index from baseline (rho's of 0.85 and 0.79, respectively, p<0.0001) and was progressively higher across close-out glucose tolerance status (diabetes, IGT, NGT). In logistic models including only anthropometric and fasting measurements, M(Q) outperformed both Matsuda and fasting insulin in predicting incident diabetes. Conclusions: In IGT subjects, Quantose M(Q) parallels changes in insulin sensitivity and glucose tolerance with pioglitazone therapy. Due to its strong correlation with improved insulin sensitivity and its ease of use, Quantose M(Q) may serve as a useful clinical test to identify and monitor therapy in insulin resistant patients.
    Journal of Clinical Endocrinology &amp Metabolism 01/2015; 100(5):jc20143824. DOI:10.1210/jc.2014-3824 · 6.31 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The chemokine RANTES plays a key role in inflammation, cell recruitment and T cell activation. RANTES is heterogenic and exists as multiple variants in vivo. Herein we describe the development and characterization of a fully quantitative mass spectrometric immunoassay (MSIA) for analysis of intact RANTES and its proteoforms in human serum and plasma samples. The assay exhibits linearity over a wide concentration range (1.56 - 200ng/mL), intra- and inter-assay precision with CVs <10%, and good linearity and recovery correlations. The assay was tested in different biological matrices, and it was benchmarked against an existing RANTES ELISA. The new RANTES MSIA was used to analyze RANTES and its proteoforms in a small clinical cohort, revealing the quantitative distribution and frequency of the native and truncated RANTES proteoforms. In the last two decades, RANTES has been studied extensively due to its association with numerous clinical conditions, including kidney-related, autoimmune, cardiovascular, viral and metabolic pathologies. Although a single gene product, RANTES is expressed in a range of cells and tissues presenting with different endogenously produced variants and PTMs. The structural variety and population diversity that has been identified for RANTES necessitate developing advanced methodologies that can provide insight into the protein heterogeneity and its function and regulation in disease. In this work we present a simple, efficient and high-throughput mass spectrometric immunoassay (MSIA) method for analysis of RANTES proteoforms. RANTES MSIA can detect and analyze RANTES proteoforms and provide an insight into the endogenous protein modifications. Copyright © 2014. Published by Elsevier B.V.
    Journal of Proteomics 12/2014; 116. DOI:10.1016/j.jprot.2014.12.011 · 3.93 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The oxidative modification of apolipoprotein A-I’s methionine148 (M148) is associated with defective HDL function in vitro. Multiple reaction monitoring (MRM) is a mass spectrometric technique that can be used to quantitate post-translational modifications. In this study, we developed an MRM assay to monitor the abundance ratio of the peptide containing oxidized M148 to the native peptide in ApoA-I. Measurement of the oxidized-to-unoxidized-M148 ratio was reproducible (CV < 5%). The extent of methionine M148 oxidation in the HDL of healthy controls, and type 2 diabetic participants with and without prior cardiovascular events (CVD) were then examined. The results suggest a significant increase in the relative ratio of the peptide containing oxidized M148 to the unmodified peptide in the HDL of participants with diabetes and CVD (p < 0.001), compared to participants without CVD. Monitoring the abundance ratio of the peptides containing oxidized and unoxidized M148 by MRM provides a means of examining the relationship between M148 oxidation and vascular complications in CVD.
    12/2014; 4-5. DOI:10.1016/j.trprot.2014.10.001
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective To examine the effect of intensive glycemic control on cardiovascular disease events (CVD) among the major race/ethnic groups in a post-hoc analysis of the VADT. Materials and Methods Participants included 1111 non-Hispanic Whites, 307 Hispanics and 306 non-Hispanic Blacks randomized to intensive or standard glucose treatment in VADT. Multivariable Cox proportional hazards models were constructed to assess the effect of intensive glucose treatment on CVD events among race/ethnic groups. Results Mean age was 60.4 years and median follow-up was 5.6 years. By design, modifiable risk factors were managed equally well in both treatment arms and only differed modestly between race/ethnic groups. HbA1c decreased significantly from baseline with intensive glucose treatment in each race/ethnic group, with a trend for a greater response in Hispanics (P = 0.01 for overall comparison between groups). Intensive glucose treatment was associated with reduced risk of CVD events for Hispanics but not for others (hazard ratios ranged from 0.54 to 0.75 for Hispanics whereas they were consistently close to 1 for others). Sensitivity analyses with different definitions of race/ethnicity or limited to individuals free of previous known CVD yielded similar results. Conclusions The results of these analyses support the hypothesis that race/ethnicity is worthy of consideration when tailoring intensive treatment for individuals with long-standing type 2 diabetes. However, additional studies are needed to confirm the findings of this post-hoc analysis.
    Metabolism 10/2014; 64(2). DOI:10.1016/j.metabol.2014.10.010 · 3.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Insulin resistance is a significant factor in the development of type 2 diabetes mellitus, however the connection between the Western diet and the development of insulin resistance has not been fully explained. Dietary macronutrient composition has been examined in a number of articles, and diets enriched in saturated fatty acids, and possibly in fructose, appear to be most consistently associated with the development of insulin resistance. However, mechanistic insights into the metabolic effects of such diets are lacking, and merit further study.
    Metabolism 09/2014; 64(2). DOI:10.1016/j.metabol.2014.08.013 · 3.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Evidence point to vascular dysfunction and hypoperfusion as early abnormalities in Alzheimer's disease (AD); probing their mechanistic bases can lead to new therapeutic approaches. We tested the hypotheses that β-amyloid peptide induces endothelial dysfunction and oxidative stress in human microvasculature and that response will be similar between peripheral adipose and brain leptomeningeal arterioles.
    Journal of Neuroscience Methods 07/2014; 235. DOI:10.1016/j.jneumeth.2014.06.014 · 1.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rationale: The mechanisms underlying lipotoxic/diabetic cardiomyopathy remain poorly understood. Saturated fatty acid (SFA) levels, elevated in obesity and type 2 diabetes, induce apoptosis in many cell types including cardiomyocytes. Signaling pathways, including the p38 alpha mitogen-activated kinase (MAPK)-dependent pathway, have been implicated in apoptosis due to a diverse range of insults. Objective: We tested the hypothesis that SFA-induced cardiomyocyte apoptosis is dependent on p38 alpha, activation. Methods and results: Human adult ventricular cardiomyocytes (AC16 cells) were exposed to high physiological levels of palmitate (PA), a SFA. The apoptotic response was measured using annexin-V by flow cytometry, and the p38 alpha-dependent pathway was evaluated using a p38 inhibitor PD169316, and by p38 alpha, small interfering RNA (siRNA) knockdown. PA exposure for 16 h dose-dependently increased apoptosis in AC16 cardiomyocytes (control: 2.6 +/- 0.6%, 150 mu M PA: 3.5 +/- 0.9%, 300 mu M PA: 11.5 +/- 1.6%, n = 4, p < 0.01). PA did not change total p38 alpha, protein levels, but increased p38 alpha, phosphorylation dose-dependently (n = 5, p <0.01). PD169316 tended to reduce PA-induced apoptosis (n = 4, p = 0.05). Specific p38 alpha siRNA markedly reduced the expression of p38 alpha but not p38 beta (n = 3, p < 0.0001), and dose-dependently attenuated PA-induced apoptosis (control siRNA: 7.7 +/- 1.0%, 300 mu M PA: 34.4 +/- 5.0%, 300 mu M PA + 30 pmol siRNA: 23.7 +/- 4.4%, 300 mu M PA + 60 pmol siRNA: 19.7 +/- 2.6%, 300 mu M PA + 120 pmol siRNA: 17.3 +/- 2.8%, n = 4, p < 0.0001). Conclusions: These results demonstrate that PA induces p38 alpha activation, and reducing p38 alpha expression attenuates PA-induced cardiomyocyte apoptosis. Our results support a potential mechanism by which high plasma SFA levels through p38 alpha activation may lead to the development of lipotoxic/diabetic cardiomyopathy. Published by Elsevier Inc.
    Biochemical and Biophysical Research Communications 06/2014; 450(1). DOI:10.1016/j.bbrc.2014.06.023 · 2.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Our objective was to examine the role of hypertriglyceridemia on the capacity of HDL to facilitate ABCA-1 mediated cholesterol efflux in type 2 diabetes (T2DM). Methods HDL mediated cholesterol efflux through the ABCA-1 transporter was measured using BHK cell lines in samples of 71 participants with T2DM in presence or absence of high triglyceride levels (TG). Additionally, HDL mediated efflux was measured in 13 diabetic and non-diabetic participants fasting and four hours after a high-fat test challenge. Results HDL mediated cholesterol efflux function was increased in participants with T2DM with hypertriglyceridemia when compared to participants with T2DM without hypertriglyceridemia (efflux ratio mean ± standard deviation (SD), T2DM + TG: 1.17 ± 0.25 vs. T2DM – TG: 1.03 ± 0.19, p = 0.0098). In the fat challenge study, we observed a significant increase in ABCA-1 mediated cholesterol efflux capacity following an ingestion of high-fat test meal by participants in both groups of T2DM (n = 6, efflux ratio, mean ± SD, pre: 0.86 ± 0.4 vs. post: 1.34 ± 0.6, p = 0.01) and non-diabetic participants (n = 7, efflux ratio mean ± SD pre : 1.24 ± 0.31 vs. post: 1.39 ± 0.42, p = 0.04) that was partly explained by the difference in CETP activity (r = 0.6, p = 0.03). Conclusion Our study suggests that high triglyceride levels facilitate ABCA-1 mediated efflux function of HDL in part by activating CETP.
    Metabolism: clinical and experimental 05/2014; DOI:10.1016/j.metabol.2014.03.001 · 3.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE Plasma adiponectin levels are reduced in type 2 diabetes mellitus (T2DM) and other insulin-resistant states. We examined whether plasma adiponectin levels at baseline and after pioglitazone treatment in impaired glucose tolerance (IGT) subjects were associated with improved insulin sensitivity (SI) and glucose tolerance status.RESEARCH DESIGN AND METHODSA total of 602 high-risk IGT subjects in ACT NOW were randomized to receive pioglitazone or placebo with a median follow-up of 2.4 years.RESULTSPioglitazone reduced IGT conversion to diabetes by 72% in association with improved β-cell function by 64% (insulin secretion/insulin resistance index) and increased tissue sensitivity by 88% (Matsuda index). In pioglitazone-treated subjects, plasma adiponectin concentration increased threefold from 13 ± 0.5 to 38 ± 2.5 μg/mL (P < 0.001) and was strongly correlated with the improvement in SI (r = 0.436, P < 0.001) and modestly correlated with glucose area under the curve during oral glucose tolerance test (r = 0.238, P < 0.005) and insulin secretion/insulin resistance index (r = 0.306, P < 0.005). The increase in adiponectin was a strong predictor of reversion to normal glucose tolerance and prevention of T2DM. In the placebo group, plasma adiponectin did not change and was not correlated with changes in glucose levels. There was an inverse association between baseline plasma adiponectin concentration and progression to diabetes in the placebo group but not in the pioglitazone group.CONCLUSIONS Baseline adiponectin does not predict the response to pioglitazone. The increase in plasma adiponectin concentration after pioglitazone therapy in IGT subjects is strongly related to improved glucose tolerance status and enhanced tissue sensitivity to insulin.
    Diabetes care 04/2014; 37(6). DOI:10.2337/dc13-1745 · 8.57 Impact Factor
  • The FASEB Journal 04/2014; 28(1). · 5.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Insulin-like growth factor 1 (IGF1) is an important biomarker for the management of growth hormone disorders. Recently there has been rising interest in deploying mass spectrometric (MS) methods of detection for measuring IGF1. However, widespread clinical adoption of any MS-based IGF1 assay will require increased throughput and speed to justify the costs of analyses, and robust industrial platforms that are reproducible across laboratories. Presented here is an MS-based quantitative IGF1 assay with performance rating of >1,000 samples/day, and a capability of quantifying IGF1 point mutations and posttranslational modifications. The throughput of the IGF1 mass spectrometric immunoassay (MSIA) benefited from a simplified sample preparation step, IGF1 immunocapture in a tip format, and high-throughput MALDI-TOF MS analysis. The Limit of Detection and Limit of Quantification of the resulting assay were 1.5 μg/L and 5 μg/L, respectively, with intra- and inter-assay precision CVs of less than 10%, and good linearity and recovery characteristics. The IGF1 MSIA was benchmarked against commercially available IGF1 ELISA via Bland-Altman method comparison test, resulting in a slight positive bias of 16%. The IGF1 MSIA was employed in an optimized parallel workflow utilizing two pipetting robots and MALDI-TOF-MS instruments synced into one-hour phases of sample preparation, extraction and MSIA pipette tip elution, MS data collection, and data processing. Using this workflow, high-throughput IGF1 quantification of 1,054 human samples was achieved in approximately 9 hours. This rate of assaying is a significant improvement over existing MS-based IGF1 assays, and is on par with that of the enzyme-based immunoassays. Furthermore, a mutation was detected in ∼1% of the samples (SNP: rs17884626, creating an A→T substitution at position 67 of the IGF1), demonstrating the capability of IGF1 MSIA to detect point mutations and posttranslational modifications.
    PLoS ONE 03/2014; 9(3):e92801. DOI:10.1371/journal.pone.0092801 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to test the hypothesis that intensive glycaemic control (INT) and higher plasma C-peptide levels in patients with poorly controlled diabetes would be associated with better eye outcomes. The incidence and progression of diabetic retinopathy (DR) was assessed by grading seven-field stereoscopic fundus photographs at baseline and 5 years later in 858 of 1,791 participants in the Veterans Affairs Diabetes Trial (VADT). After adjustment for all covariates, risk of progression (but not incidence) of DR increased by 30% for each 1% increase in baseline HbA1c (OR 1.3; 95% CI 1.123, 1.503; p = 0.0004). Neither assignment to INT nor age was independently associated with DR in the entire cohort. However, INT showed a biphasic interaction with age. The incidence of DR was decreased in INT participants ≤55 years of age (OR 0.49; 95% CI 0.24, 1.0) but increased in those ≥70 years old (OR 2.88; 95% CI 1.0, 8.24) (p = 0.0043). The incidence of DR was reduced by 67.2% with each 1 pmol/ml increment in baseline C-peptide (OR 0.328; 95% CI 0.155, 0.7; p = 0.0037). Baseline C-peptide was also an independent inverse risk factor for the progression of DR, with a reduction of 47% with each 1 pmol/ml increase in C-peptide (OR 0.53; 95% CI 0.305, 0.921; p = 0.0244). Poor glucose control at baseline was associated with an increased risk of progression of DR. INT was associated with a decreased incidence of DR in younger patients but with an increased risk of DR in older patients. Higher C-peptide at baseline was associated with reduced incidence and progression of DR.
    Diabetologia 03/2014; 57(6). DOI:10.1007/s00125-014-3199-7 · 6.88 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: HDL carries a rich protein cargo and examining HDL protein composition promises to improve our understanding of its functions. Conventional mass spectrometry methods can be lengthy and difficult to extend to large populations. In addition, without prior enrichment of the sample, the ability of these methods to detect low abundance proteins is limited. Our objective was to develop a high-throughput approach to examine HDL protein composition applicable to diabetes and cardiovascular disease (CVD). We optimized two multiplexed assays to examine HDL proteins using a quantitative immunoassay (Multi-Analyte Profiling- MAP) and mass spectrometric-based quantitative proteomics (Multiple Reaction Monitoring-MRM). We screened HDL proteins using human xMAP (90 protein panel) and MRM (56 protein panel). We extended the application of these two methods to HDL isolated from a group of participants with diabetes and prior cardiovascular events and a group of non-diabetic controls. We were able to quantitate 69 HDL proteins using MAP and 32 proteins using MRM. For several common proteins, the use of MRM and MAP was highly correlated (p < 0.01). Using MAP, several low abundance proteins implicated in atherosclerosis and inflammation were found on HDL. On the hand, MRM allowed the examination of several HDL proteins not available by MAP. MAP and MRM offer a sensitive and high-throughput approach to examine changes in HDL proteins in diabetes and CVD. This approach can be used to measure the presented HDL proteins in large clinical studies.
    Lipids in Health and Disease 01/2014; 13(1):8. DOI:10.1186/1476-511X-13-8 · 2.31 Impact Factor
  • Diabetes 10/2013; 62(11):3920-3926. DOI:10.2337/db13-0265 · 8.47 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective To test the hypothesis that high levels of plasminogen activating inhibitor -1(PAI-1) and fibrinogen at baseline were associated with the onset and/or progression of diabetic retinopathy (DR) during the VADT.Research Design and Methods The VADT was an open-label, prospective, randomized controlled trial to test standard glycemic control (STD) compared to intensive control (INT) on cardiovascular events in patients with advanced type 2 diabetes mellitus (T2DM). Retinopathy (DR) outcomes were also collected. Incidence and progression of DR was assessed by grading 7-field stereoscopic fundus photographs at baseline and 5 years later taken in 858 of a total of 1791 participants who completed both eye examinations.ResultsOnset of DR during the study: Assignment to INT was not independently associated with decreased risk of onset of DR. However, after adjusting for multiple covariates (CVs), baseline level of PAI-1 was an independent risk factor for the onset of DR. The risk for incidence of DR increased by 12% for each 10 ng/dl increase in baseline PAI-1 concentration (OR 1.012 CI 1.00-1.024, p = 0.042).Progression of DR during the Study: Assignment to INT was not independently associated with decreased risk of progression of DR. However, there was an interaction between glycemic treatment assignment and fibrinogen level at baseline. INT was associated with decreased progression of retinopathy in those with fibrinogen less than 296 mg/dl (OR=0.55 CI 0.31- 1, p=0.03.Conclusion The results require confirmation but are consistent with greater hypercoagulabilty and inflammation, as measured by higher levels of PAI-1 and fibrinogen, being related to DR and responsiveness to INT.
    Diabetes care 10/2013; 37(2). DOI:10.2337/dc13-1193 · 8.57 Impact Factor

Publication Stats

6k Citations
723.54 Total Impact Points

Institutions

  • 2008–2015
    • Phoenix VA Health Care System
      Phoenix, Arizona, United States
  • 2010–2014
    • The University of Arizona
      Tucson, Arizona, United States
  • 2013
    • University of Texas Health Science Center at San Antonio
      San Antonio, Texas, United States
  • 2009
    • Arizona State University
      Phoenix, Arizona, United States
  • 2006–2007
    • Stanford University
      • Department of Medicine
      Palo Alto, California, United States
    • United States Department of Veterans Affairs
      Bedford, Massachusetts, United States
  • 2003–2006
    • U.S. Department of Veterans Affairs
      Washington, Washington, D.C., United States
    • Stanford Medicine
      • Department of Medicine
      Stanford, California, United States
  • 1990–2005
    • University of California, San Diego
      • • Division of Endocrinology & Metabolism
      • • Department of Medicine
      San Diego, California, United States
  • 2002
    • University of Southern California
      • School of Pharmacy
      Los Angeles, California, United States
  • 1998
    • Indiana University-Purdue University Indianapolis
      Indianapolis, Indiana, United States